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Edited by Gianni CesareniAbstract DNA vectors that express short hairpin RNAs
(shRNAs) provide a new tool for reverse genetic analysis for
selective long-term reduction of gene expression in mammalian
cells. Using shRNA constructs with a cytomegalovirus promoter
and an actin intron between the hairpins for stabilization, we
reduce expression of an exogenously expressed gene, GFP and
the endogenous protein, Translin-associated factor X (TRAX), in
stably transfected Hela cell lines. The reduction of TRAX in
Hela cells causes reduced cell proliferation. This decrease is
speciﬁc as there is no equivalent reduction of the TRAX
interacting protein, Testis brain RNA-binding protein, or any
signiﬁcant increase in a number of interferon-related target
genes.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
Keywords: RNA interference; Translin associated protein X;
Cell proliferation1. Introduction
Translin and its mouse ortholog, Testis brain RNA-binding
protein (TB-RBP), are highly conserved and ubiquitously ex-
pressed DNA- and RNA-binding proteins with proposed
functions in mitotic cell division [1,2], chromosomal translo-
cations [3–5], stabilization, transport, and translational sup-
pression of speciﬁc mRNAs [6–8]. Mice lacking TB-RBP are
viable and when heterozygotes were bred, a normal Mendelian
distribution was obtained [2]. However, the TB-RBP null mice
were 10–30% smaller than their littermates, accumulated vis-
ceral fat, had a thin carnosus panniculus, and showed behav-
ioral changes. The males had abnormal seminiferous tubules
and reduced sperm counts, while the females were subfertile
and had reduced litter sizes.
In addition to these phenotype changes in mice lacking
TB-RBP, one of the TB-RBP interacting proteins, Translin
associated protein X (TRAX) [9,10] was also aﬀected, being
reduced to 50% in heterozygotes and absent in the nulls. This
loss of TRAX occurred post-transcriptionally as equal
amounts of TRAX mRNA were detected in tissues from wild
type, heterozygous, and homozygous mice [2]. Defects at the
cellular level were also detected. Embryonic ﬁbroblasts
(MEFs) from TB-RBP null mice proliferated more slowly than
MEFs isolated from their heterozygous or wild type litter-* Corresponding author. Fax: +1-215-573-5408.
E-mail address: nhecht@mail.med.upenn.edu (N.B. Hecht).
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died this defect [11]. However, upon reintroduction of TB-
RBP, TRAX also began to accumulate. TB-RBP is needed to
stabilize TRAX by forming hetero-oligomers because in the
absence of TB-RBP, TRAX becomes ubiquitinated and de-
graded [11]. Thus, the concomitant loss of both TB-RBP and
TRAX in TB-RBP deﬁcient mice makes it diﬃcult to relate
speciﬁc cellular functions to TB-RBP, to TRAX, or to both
proteins.
Here, we utilize an intron-based cytomegalovirus (CMV)
driven short hairpin vector to selectively reduce expression of
TRAX in long-term cultures without decreasing TB-RBP
levels. We ﬁnd that TRAX is essential to maintain normal
rates of cell proliferation in cultured cells.2. Materials and methods
2.1. Intron-based shRNAs system
A long pair of ‘‘shagging’’ primers containing two fragments from
the GFP coding region with a 3–8 bp spacer was synthesized as fol-
lows: forward primer-cacccta cgg caa gct gac cct gaa gtt cat cta tat
ata tag gct acg tcc agg agc gca cca tct tcg ctt gca ttg atc aca cgt gga
tga ccc agg tga gtg gcc cgc and reverse primer-a cct acg
gca agc tga ccc tga agt tca tgg ccg gct acg tcc agg agc gca cca tct tca
att cac gtg tga tca ctc aaa cat gat ctg taa ggc ag (underlining indicates
sequences from the GFP coding region). Genomic DNA from Hela
cells or primary human ﬁbroblasts was used as template and the b-
actin intron C [12] was ampliﬁed and cloned into a pLenti6/V5-D-
TOPO vector (Invitrogen, Carlsbad, CA). A similar pair of primers
containing two fragments of the human TRAX coding region was
designed with the following primers: forward primer-
caccatt cat ctt cac ccg tga tgt tgg cct ta atc att tca gca gga act tga
tgc aag cca ggt gag tgg ccc gct a and reverse primer-
att cat ctt cac ccg tga tgt tgg cct ggg atc att tca gca gga act tga tgc
aag ctc aaa cat gat ctg taa ggc (underlining indicates sequences from
the TRAX coding region). PCR products were cloned into a lentivirus
vector. The pLentivirus vectors containing the inverted repeat of
GFP and TRAX were named pLenti6/GFPi and pLenti6/TRAXi,
respectively.
2.2. Lentivirus infection
293FT cells (Invitrogen, Carlsbad, CA) were cultured in complete
culture medium (DMEM containing 10% FBS, 2 mM L-glutamine and
1% penicillin/streptomycin) and Geneticin (500 lg/ml). The day before
transfection, 5 106 293FT cells were plated onto 100 mm plates with
10 ml of culture medium. On the day of transfection, the culture me-
dium was replaced with 5 ml of growth medium containing serum
without antibiotics. ViraPower Packaging Mix (Invitrogen, Carlsbad,
CA) (9 lg) and 3 lg of pLenti6/GFPi or pLenti6/TRAXi were mixed
with 1.5 ml Opti-MEM I medium without serum. At the same time, 36
ll of Lipofectamine 2000 (Gibco BRL, Rockville, MD) was added to
the Opti-MEM I medium. The DNA and Lipofectamine 2000 were
gently mixed, incubated for 20 min at room temperature and added to
the DNA-Lipofectamine 2000 complexes dropwise. After gentleation of European Biochemical Societies.
Fig. 1. Selective reduction of gene expression in human cell lines by an
intron-based shRNA vector. (a) Schematic diagram showing the for-
mation of intron-based shRNA vectors. Fragments of 28 and 29 bp
from the coding region of GFP with a small spacer and their inverted
repeats linked by human b-actin intron C were cloned into a mam-
malian expression vector driven by the CMV promoter. The intron-
222 S. Yang, N.B. Hecht / FEBS Letters 576 (2004) 221–225mixing, the cells were incubated overnight at 37 C in a CO2 incubator.
The next day, the medium was replaced with complete culture medium
and the virus-containing supernatants were harvested 72 h post-
transfection. The cell debris was removed by centrifugation at 3000
rpm for 15 min at 4 C and the viral supernatants were pipetted into
cryovials in 1 ml aliquots and stored at )80 C. U2, H1299, HFF and
Hela cells (ATCC, Manassas, VA), propagated with complete culture
medium (DMEM) except U2, were cultured in McMoy’s 5A medium
(Gibco BRL, Rockville, MD) and plated at 5 105 cells per 100 mm
plate. The next day, the virus-containing supernatants were diluted 3-
fold and added to the cells with polybrene (6 lg/ml) (Sigma, St. Louis,
MO). The following day, the medium was replaced with complete
culture medium. Seventy two hours after transfection, the medium was
replaced with fresh medium containing 50 lg/ml of blasticidin. This
was repeated every 3–4 days to produce the stably transfected cells
expressing GFP or TRAX shRNAs. The colonies were monitored for 3
weeks for pLenti6/GFPi and 6 weeks for pLenti6/TRAXi transduction
and picked with clone cylinders (Sigma, St. Louis, MO).
2.3. Western blotting and ﬂow cytometry
U2, H1299, HFF and Hela cell derived lines expressing shRNAs of
GFP and TRAX were propagated as above and maintained with
blasticidin (30 lg/ml). HA tagged TB-RBP was ampliﬁed using a pair
of primers containing the HA TB-RBP-coding sequence in the forward
primer (50 primer, gccgctagcgccgccaccatgggatcctacccttacgacgttcctgat-
tacgctagcctcgaattc-atgtctgtgagcgagatcttc; 30 primer, gcctctagactatttttc-
accacaagc) and cloned into the pCI-Neo expression vector (Promega,
Madison, WI). The cell lines expressing GFP shRNAs were transfected
with the pEGFP-C1 vector (Clontech, Palo Alto, CA) and analyzed 72
h after transfection. Whole cell lysates were prepared in RIPA buﬀer
[(1% Triton X-100, 0.5% sodium deoxycholate, and 0.1% SDS, con-
taining freshly added 1/10 volume of protease inhibitor cocktail)
(Sigma, St. Louis, MO) in PBS], incubated on ice for 20 min, and
centrifuged at 12 000g for 10 min at 4 C. The protein concentration
in the supernatant was quantitated with a BCA Protein Assay Kit
(Pierce, Rockford, IL). Aliquots (20 lg) were mixed with 2SDS load-
ing buﬀer containing 0.35 M 2-mercaptoethanol, subjected to 10%
SDS-PAGE and then transferred onto PVDF membranes (Millipore,
Bedford, MA). Primary antibodies for mouse anti-GFP (Roche, In-
dianapolis, IN), mouse anti-HA (Roche Diagnostics, Germany),
mouse anti-a-tubulin (Sigma, St. Louis, MO), aﬃnity puriﬁed anti-TB-
RBP [13] and mouse anti-TRAX (Pharmagen, San Diego, CA) were
used to detect each of the proteins. Horseradish peroxidase-conjugated
anti-mouse IgG antibody, protein A and the Enhanced Chemilumi-
nescent (ECL) Detection Kit (Amersham Pharmacia, Piscataway, NJ)
were used to visualize each protein. Hela cell lines expressing shRNAs
were trypsinized 72 h after transfection. Cells were resuspended in
complete DMEM, centrifuged at 3000g for 5 min, and washed twice
with ice cold PBS. Samples were sorted using an EPICS XL (Beckman-
Coulter, Miami, FL). The Hela cell lines expressing TRAX shRNAs
were propagated and maintained in blasticidin (30 lg/ml). When the
cells reached conﬂuency, whole cell lysates were harvested and ana-
lyzed by Western blotting as described above. TRAX expression was
measured by densitometry using ImageQuant software and relative
expression levels were normalized to TB-RBP and the tubulin loading
control. Hela cell lines expressing TRAX and GFP shRNAs and mock
infected Hela cells were plated at 5 105 in 100 mm dishes in duplicate.
Cell numbers were counted every 24 h for 5 consecutive days. At 72 h,
cells were harvested and sorted by FACs for cell cycle analysis. Brieﬂy,
the cells were resuspended in 1 ml of )20 C methanol and incubated
for a minimum of 30 min on ice. The cells were then centrifuged at
3000 g at 4 C for 5 min, the supernatants aspirated, and 400–500 ll of
propidium iodide staining solution (0.15 mM propidium iodide, 0.1%
Triton X-100 and 1 mg/ml RNase (Sigma, St. Louis, MO)) was added.junction sequence is predicted to be spliced during pre-mRNA
processing to produce a loopless hairpin structure similar to miRNA
precursors. The shRNAs are further processed by Dicer to siRNAs
that guide cleavage of the cognate mRNA. (b) Selective reduction of an
exogenously expressed mRNA, GFP in three human cell lines, U2,
H1299 and HFF, following infection with a lentivirus construct ex-
pressing GFP shRNAs. Antibiotic resistant pools of cells were selected
and transfected with pEGFP and control HA tagged TB-RBP. Seventy
two hours after transfection, whole cell lysates were prepared and
aliquots (25 lg) were analyzed by Western blotting. GFP expression
was measured in the control parental line, in a mock transfection, and
following transfection with the GFP shRNAs cassette.2.4. Quantitative real-time RT-PCR
Total Hela cell RNA was isolated with the Rnase Easy kit (Qiagen,
Valencia, CA). RNA was incubated with deoxyribonuclease I (Invit-
rogen,Carlsbad, CA) for 15 min at room temperature and the DNase I
was inactivated by addition of 1 ll of 25 mM EDTA to the reaction
mixture and heated for 10 min at 65 C. The RNA samples were
transcribed into cDNAs using SUPERSCRIPT RT (Invitrogen,
Carlsbad, CA). The primers for real-time RT-PCR were designed using
Primer Express 1.5 software. The following primers were synthesized.
OAS1, forward primer: agg tgg taa agg gtg gct cc, reverse primer: acaacc agg tca gcg tca gat; MX1, forward primer: acctgtgcagccagtatgagg,
reverse primer: agcccgcagggagtcaat; ISG20, forward primer: cctgc-
acaagagcatccaga, reverse primer: cgttgccctcgcatcttc; IFI44, forward
primer: tggcagtgacaactcgtttga, reverse primer: ccgcttccctccaaaa; IFIT1,
forward primer: gccacaaaaaatcacaagcca, reverse primer: ccattgtctg-
gatttaagcgg; TRAX, forward primer: ccg tga tgt tgg cct tta aat c, re-
verse primer: cct atg gag gag aaa aat tgt cct t; TB-RBP, forward
primer: agc gtg act gct gga gac tac tc, reverse primer: gaa aac cgg aat
cca gct ca; and GAPDH, forward primer: aac gac ccc ttc att gac ctc,
reverse primer: ttg aat ttg ccg tga gtg ga. Real-time RT-PCR was
performed with the ABI PRISM 7700 sequence detection system
(Applied Biosystems, Foster City, CA) using SYBR green. Relative
gene expression was quantitated by the comparative CT method as
described in the user’s manual. In three Hela cell lines, samples were
examined in duplicate and the relative amounts of TRAX, TB-RBP,
MX1, ISG20, IFI44, IFIT1 and OAS1 mRNAs were normalized to
Hela GAPDH mRNA.3. Results and discussion
3.1. Intron-based shRNA construct
Many RNA interference methodologies are available to se-
lectively reduce gene expression in cells and animals [14–19].
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maintain normal rates of cellular proliferation, we have uti-
lized a novel intron-based shRNA vector driven by a CMV
promoter. Two short fragments from the GFP coding region
and its inverted repeat linked to a human b-actin intron C [12]
were cloned into a lentivirus mammalian expression vector
driven by a CMV promoter. The intron contributes to the
stability of the two short perfect inverted-repeat sequences,
which are not a prerequisite for the speciﬁcity of gene silencing
(Fig. 1(a)). The intron-based construct elicits total silencing in
plants when spliced during pre-mRNA processing to produce a
loopless hairpin structure [20]. The fold back shRNA helix
similar to the precursors of miRNAs [21,22] is readily pro-
cessed by Dicer and assembled into an RNA-induced silencing
complex (RISC) to guide sequence speciﬁc cleavage of mRNA
(Fig. 1(a)).Fig. 2. Exogenously expressed GFP is reduced in stably transduced
Hela cell lines expressing two fragments of GFP shRNAs. (a) Analysis
of GFP expression by FACs analysis. Stably selected Hela cell lines
were transfected with the pEGFP vector and 72 h later cells were
harvested and analyzed by FACs. A negative control, untransfected
Hela cells (Hela), was sorted as GFP-negative cells (rear peak indicates
GFP-negative Hela cells and the forward peak indicates GFP-positive
cells); control transfected Hela cells expressing GFP transduced with
lentivirus without GFP shRNAs; and seven diﬀerent stably selected
Hela cell lines expressing GFP shRNAs (showing reduced GFP ex-
pression in forward peaks) are illustrated. (b) Western blot showing
expression level of GFP in cell lysates (25 lg) from stably transduced
Hela cell lines. Lane 1, Hela cell control; lane 2, GFP transfection
control; lanes 3–9, seven diﬀerent stably selected Hela lines. Upper
panel, GFP expression; middle panel, endogenous TRAX; lower panel,
tubulin loading control.
Fig. 3. Endogenous TRAX is selectively reduced in Hela cell lines
expressing two TRAX shRNAs. Hela cells were infected with lentivirus
containing two diﬀerent fragments of 27 bp from the TRAX coding
region with a small spacer and its inverted repeat linked by a human b-
actin intron C. Three clones expressing TRAX shRNAs and four
clones expressing GFP shRNAs were analyzed by Western blotting.
(a) Upper panel, TRAX; middle panel, TB-RBP; lower panel, tubulin.
(b) TRAX expression was quantitated by densitometry using Image-
Quant software and its percentage of expression was normalized to
that of control Hela cells.
Fig. 4. Reduction of TRAX in Hela cell lines causes a slower growth
rate and an abnormal cell cycle. (a) Cells (5 105) from three Hela cell
lines expressing TRAX shRNAs, three cell lines expressing GFP
shRNAs and one Hela cell control were plated onto 100 mm dishes.
Cells were trypsinized and counted every 24 h for ﬁve consecutive days.
Hela cell controls (diamonds), GFP expressing cell lines (squares) and
TRAX expressing cell lines (triangles). (b) Cells were propagated as
above, harvested at 72 h, stained with PI and analyzed by FACs. The
G2/M phase in Hela cell lines expressing TRAX shRNAs is signiﬁ-
cantly increased. Asterisk indicates signiﬁcant diﬀerences between Hela
cell controls and Hela cell lines expressing GFP siRNAs (P < 0:01).
Table 1
Real-time RT-PCR analysis of gene expression in Hela cell lines expressing shRNAs
Clone types TRAX TB-RBP OAS1 MX1 ISG20 IFI44 IFIT1
Hela 1 (0.95–1.04) 1 (0.98–1.01) 1 (0.99–1.00) 1 (0.67–1.48) 1 (0.98–1.01) 1 (0.98–1.01) 1 (0.75–1.33)
Hela/GFPi 1.91 (1.74–2.09) 0.92 (0.88–0.95) 2.97 (2.74–3.22) 1.91 (1.76–2.06) 1.59 (1.45–1.73) 0.97 (0.79–1.19) 0.49 (0.46–0.53)
Hela/TRAXi 0.007 (0.002–0.01) 1.73 (1.45–2.06) 0.67(0.56–0.80) 0.24 (0.21–0.28) 2.09(1.79–2.45) 0.13 (0.10–0.16) 0.02 (0.02–0.02)
Real-time PCR was performed with the ABI PRISM 7700 sequence detection system using the SYBR green PCR master mix. Relative gene
expression was analyzed by the comparative CT method as described in the user’s manual. Samples were assayed in duplicate. The relative amounts
of TRAX, TB-RBP, OAS1, MX1, ISG20, IFI44 and IFIT1 mRNAs were compared to Hela GAPDH mRNA levels.
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expression in both transiently and stably transduced cells
To determine if we can speciﬁcally reduce the expression of a
gene with our shRNA constructs, we have infected three hu-
man derived cell lines, U2, H1299 and HFF, with a lentivirus
containing a GFP shRNA expression cassette and we have
selected for pools of antibiotic resistant cells. Seventy two
hours after transfection with GFP and tagged TB-RBP vec-
tors, whole cell lysates were prepared and analyzed by Western
blotting (Fig. 1(b)). The blot reveals a selective reduction of
GFP, while the HA tagged TB-RBP and two endogenous
proteins, b-actin and a-tubulin, remain unchanged in these
three human lines (Fig. 1(b)).
To extend this approach to stably transfected lines of cells,
we infected Hela cells with the lentivirus construct and ob-
tained seven stable Hela cell clones which express GFP shR-
NAs. Seventy two hours after the GFPi Hela cell lines were
transfected with the pEGFP vector, the cells were sorted by
FACs (Fig. 2(a)). GFP was reduced in the seven Hela GFPi
lines (forward peaks). The reduction of GFP in the transfected
Hela GFPi lines was conﬁrmed by Western blotting (Fig. 2(b),
lanes 3–9). The blot reveals a variable but substantial reduc-
tion of exogenously expressed GFP, while the endogenous
proteins, TRAX and tubulin, were unchanged.
3.3. The CMV-shRNA vector selectively suppresses TRAX
expression leading to reduced cell proliferation
Previous studies with mice lacking TB-RBP [2] and MEFs
(MEFs) derived from TB-RBP null mice revealed that the
loss of TB-RBP caused an equivalent loss of its partner
protein, TRAX, and the MEFs from null mice showed a
slower growth rate [11]. Having established that our intron-
based vector works with the exogenous GFP gene, we tar-
geted TRAX in Hela cells with a similar vector expressing
TRAX shRNAs to determine whether TRAX deﬁciency af-
fected cell proliferation. Western blotting revealed that three
stable Hela cell TRAXi lines (TRAX 1, 2 and 3) express
reduced amounts of TRAX compared to control Hela and
Hela GFP (GFP 1–4) cell lines (Fig. 3). The intron-based
shRNAs vector selectively reduced TRAX, while TB-RBP
remained unchanged (Fig. 3). Most importantly, the Hela
cells expressing TRAX shRNAs proliferate more slowly
(Fig. 4(a)) with a build up of cells in the G2/M phase
(Fig. 4(b)). Of 15 lines of Hela cells expressing TRAX shR-
NAs, 14 out of 15 had a slower growth rate (data not
shown). A similar slower growth rate of NIH 3T3 cells was
observed when TRAX levels were transiently reduced with
TRAX siRNAs [11]. To conﬁrm that the reduction of TRAX
expression was due to the speciﬁc loss of TRAX mRNAs, we
measured TRAX mRNA levels by real-time RT-PCR. TRAX
mRNA was reduced to about 1% of the level of control Helacells and the Hela cell lines expressing GFP shRNAs (Table
1), establishing that the intron-based vectors act through
siRNAs as reported for other shRNA vectors [14–19].
3.4. The intron-based vector does not induce an interferon
response
To rule out the possibility that the intron-based vectors used
in this study were triggering a generalized interferon response,
we analyzed by real-time RT-PCR a panel of interferon target
genes, including 2050-oligoadenylate synthetase (OAS1), inter-
feron-inducible protein p78 (MX1), interferon stimulated gene
20 (ISG20), interferon-induced protein 44 (IFI44) and inter-
feron-induced protein with tetratricopeptide repeats 1 (IFIT1)
known to be induced by H1 or U6 driven shRNA vectors [23].
Compared to control Hela cells, the mRNA levels of the in-
terferon markers in Hela cell lines expressing GFP or TRAX
shRNAs only ﬂuctuated slightly (Table 1). The decreases of
MX1, IF144 and IFIT1 mRNAs in cell lines expressing TRAX
shRNAs are likely due to the slower growth rate of the cells
[11]. The non-induction of the interferon mRNAs indicates
that the reduction in TRAX was not part of a global interferon
response in the infected cells. We propose that the miRNA-like
precursors produced by intron-based vectors can ‘‘knock
down’’ gene expression for a wide range of genes in a variety of
mammalian cells with speciﬁcity. This approach, using shRNA
vectors containing a CMV promoter and inverted repeat se-
quences that are stabilized by an intron, could also be useful in
generating loss-of-function phenotypes in transgenic animals.
The success of this strategy indicates that gene silencing can be
successfully obtained in mammalian cells using an expression
cassette transcribing a short hairpin without the use of an
RNA polymerase III promoter.
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